Organogenesis Holdings Inc (ORGO) Stock Price, Quote & News

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 575 0775

Website: organogenesis.com

Address:

85 Dan Road, Canton, United States

josegodoy Jul. 24 at 8:36 PM

$ORGO watching $4.50…. Will adjust (after a better look this weekend)

0 · Reply

Look_2_Learn Jul. 22 at 7:52 PM

$ORGO nice climb today. Where do we end up tomorrow? Looks like $7 price target may be accurate. Cheers 🍻

1 · Reply

MRB250 Jul. 17 at 11:36 PM

$ORGO let’s get it 4:20 now support

0 · Reply

Parnell8 Jul. 16 at 1:59 PM

$ORGO cms update huge positive , should be $7

1 · Reply

Reesifer Jul. 15 at 3:20 PM

$ORGO wouldve been niceee

0 · Reply

DARKP00L Jul. 15 at 3:19 PM

$ORGO this stock is drawing major attention! Keep watch for market moves!

0 · Reply

Mobagri Jul. 15 at 3:05 PM

$ORGO whoever bought at the dip made a killing.

1 · Reply

DARKP00L Jul. 15 at 2:33 PM

$ORGO momentum building! Stock attracting attention, could be a mover!

0 · Reply

theflynews Jul. 15 at 2:05 PM

Why $ORGO and $MDXG Are Sinking Today. https://www.youtube.com/shorts/kN5sCGALxo0

0 · Reply

Mobagri Jul. 15 at 1:57 PM

$ORGO https://stocks.apple.com/AzlojY0FATQuVOwoIvBVskg This is great news to get rid of competition

0 · Reply

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Jul 15, 2025, 9:00 AM EDT - 13 days ago

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Jun 9, 2025, 5:39 PM EDT - 7 weeks ago

Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

May 11, 2025, 10:14 AM EDT - 2 months ago

Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 2 months ago

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Apr 11, 2025, 4:05 PM EDT - 3 months ago

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Apr 7, 2025, 4:05 PM EDT - 4 months ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Feb 27, 2025, 8:27 PM EST - 5 months ago

Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 5 months ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Jan 27, 2025, 7:30 AM EST - 6 months ago

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Nov 22, 2024, 4:05 PM EST - 8 months ago

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Nov 15, 2024, 9:25 AM EST - 9 months ago

Organogenesis Commends Final LCDs

Nov 12, 2024, 11:02 PM EST - 9 months ago

Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 9 months ago

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Nov 11, 2024, 5:05 PM EST - 9 months ago

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Oct 16, 2024, 7:30 AM EDT - 10 months ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Oct 1, 2024, 4:05 PM EDT - 10 months ago

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Sep 4, 2024, 4:05 PM EDT - 11 months ago

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Aug 8, 2024, 11:08 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

May 9, 2024, 9:01 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Feb 29, 2024, 11:06 PM EST - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Feb 12, 2024, 7:30 AM EST - 1 year ago

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb 8, 2024, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Nov 9, 2023, 10:16 PM EST - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Oct 5, 2023, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Sep 28, 2023, 9:15 AM EDT - 1 year ago

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Jul 20, 2023, 11:31 AM EDT - 2 years ago

Organogenesis: Solid Revenue Generation From A Hyper-Trading Wound Care Company

Jul 10, 2023, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CABA CYH EXAS MRNA NVAX PFE RARE

May 10, 2023, 11:50 PM EDT - 2 years ago

Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript

May 10, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

Apr 27, 2023, 7:30 AM EDT - 2 years ago

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

Apr 10, 2023, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Organogenesis Applauds Findings from the Office of Inspector General

Mar 1, 2023, 10:17 PM EST - 2 years ago

Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Call Transcript

Mar 1, 2023, 4:02 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

Mar 1, 2023, 4:01 PM EST - 2 years ago

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Feb 9, 2023, 7:30 AM EST - 2 years ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

josegodoy Jul. 24 at 8:36 PM

$ORGO watching $4.50…. Will adjust (after a better look this weekend)

0 · Reply

Look_2_Learn Jul. 22 at 7:52 PM

$ORGO nice climb today. Where do we end up tomorrow? Looks like $7 price target may be accurate. Cheers 🍻

1 · Reply

MRB250 Jul. 17 at 11:36 PM

$ORGO let’s get it 4:20 now support

0 · Reply

Parnell8 Jul. 16 at 1:59 PM

$ORGO cms update huge positive , should be $7

1 · Reply

Reesifer Jul. 15 at 3:20 PM

$ORGO wouldve been niceee

0 · Reply

DARKP00L Jul. 15 at 3:19 PM

$ORGO this stock is drawing major attention! Keep watch for market moves!

0 · Reply

Mobagri Jul. 15 at 3:05 PM

$ORGO whoever bought at the dip made a killing.

1 · Reply

DARKP00L Jul. 15 at 2:33 PM

$ORGO momentum building! Stock attracting attention, could be a mover!

0 · Reply

theflynews Jul. 15 at 2:05 PM

Why $ORGO and $MDXG Are Sinking Today. https://www.youtube.com/shorts/kN5sCGALxo0

0 · Reply

Mobagri Jul. 15 at 1:57 PM

$ORGO https://stocks.apple.com/AzlojY0FATQuVOwoIvBVskg This is great news to get rid of competition

0 · Reply

JarvisFlow Jul. 15 at 1:00 PM

Cantor Fitzgerald has updated their rating for Organogenesis Holdings ( $ORGO ) to Overweight with a price target of 7.

0 · Reply

OpenOutcrier Jul. 15 at 12:26 PM

$MDXG (-10.4% pre) $ORGO (-13.6% pre) MiMedx Group (MDXG), Organogenesis (ORGO) Shares Fall After CMS Proposal to Cut Spending https://ooc.bz/l/70004

0 · Reply

OpenOutcrier Jul. 15 at 12:25 PM

$ORGO $SNN $IART Organogenesis Holding (ORGO), Smith & Nephew (SNN) & Integra LifeSciences (IART) Also Fall on CMS Publication https://ooc.bz/l/70000

0 · Reply

Lynchador Jul. 15 at 8:59 AM

$ORGO $MDXG The question, Mimedx or Organogenesis , who has better products?

3 · Reply

GlobalInsights Jul. 14 at 11:01 PM

$ORGO https://www.cms.gov/newsroom/press-releases/cms-proposes-physician-payment-rule-significantly-cut-spending-waste-enhance-quality-measures-and

0 · Reply

cabeln Jul. 14 at 10:25 PM

$ORGO obviously going to effect sales but reimbursement changes wont be implanted until H1 2026. Have 328 shares. Debating on selling complete stake or riding it out

0 · Reply

stockanalysis_ Jul. 14 at 9:41 PM

After Hours Losers: $SANW $ORGO $TROO $SQFT $MDXG View the entire list here: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading

0 · Reply

Reesifer Jul. 14 at 9:36 PM

$ORGO missed that under 3 dip

0 · Reply

Du57mi73 Jul. 14 at 9:35 PM

$ORGO Has there been a release im not seeing? no new news on their website. whats going on?

2 · Reply

HypnoTrader Jul. 14 at 9:23 PM

$ORGO some reimbursement issue most likely...

1 · Reply

cabeln Jul. 14 at 9:22 PM

$ORGO pretty much just lost all my gains

0 · Reply

cabeln Jul. 14 at 9:22 PM

$ORGO well this sucks

0 · Reply

Market Cap	638.08M
Revenue (ttm)	482.04M
Net Income (ttm)	860,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.18%
Debt to Equity Ratio	0.00

Volume	610,221
Avg Vol	950,624
Day's Range	N/A - N/A
Shares Out	126.85M
Stochastic %K	100%
Beta	1.70
Analysts	Strong Sell
Price Target	$6.33